

ABSTRACT

A therapeutic product or drug for therapy of hemophilia may be produced by a simplified method including embedding genes of the blood clotting factors VIII (IX) for therapy of hemophilia in hollow nano particles obtained on expressing the protein having a particle forming function, such as hepatitis B virus surface antigen protein, in eucaryotic cells. The drug so produced is able to introduce the genes of the blood clotting factors efficaciously into liver cells with the least risk of side effects.